TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion
Brief Summary: This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to branch retinal vein occlusion (BRVO); 397 patients with BRVO were enrolled at 93 investigational sites in the United States. The study included a treatment period (6 months) and an observation period (6 months).


Options:
A: Intervention Type: DRUG; Name: pegaptanib sodium; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 2; Type: N/A; Interventions: N/A | Arm Label: 3; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 4; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 5; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 6; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 7; Type: N/A; Interventions: Other: Examination with an OCT device | Intervention Type: OTHER; Name: Examination with an OCT device; Assigned to Arm(s): 1, 3, 4, 5, 6, 7
C: Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: Ranibizumab injection 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.3 mg | Arm Label: Ranibizumab injection 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.5 mg | Intervention Type: DRUG; Name: Ranibizumab injection 0.3 mg; Assigned to Arm(s): Ranibizumab injection 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab injection 0.5 mg; Assigned to Arm(s): Ranibizumab injection 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection
D: Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: Ranibizumab injection 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.3 mg | Arm Label: Ranibizumab injection 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection | Intervention Type: DRUG; Name: Ranibizumab injection 0.3 mg; Assigned to Arm(s): Ranibizumab injection 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab injection 0.5 mg; Assigned to Arm(s): Ranibizumab injection 0.5 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Breast Cancer Survivors: Physical Activity, Inflammation, Fatigue, and Distress
Brief Summary: RATIONALE: Yoga may improve inflammation, fatigue, and depression in female breast cancer survivors.

PURPOSE: This randomized clinical trial is studying how well Hatha yoga works in improving physical activity, inflammation, fatigue, and distress in female breast cancer survivors.


Options:
A: Arm Label: Exercise Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity counseling | Arm Label: Contact Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity counseling; Assigned to Arm(s): Exercise Counseling
B: Arm Label: Arm I: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Yoga Therapy | Arm Label: Arm II: Wait-List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Yoga Therapy; Assigned to Arm(s): Arm I: Yoga Therapy
C: Arm Label: Telerehabilitation group; Type: EXPERIMENTAL; Interventions: Behavioral: Telerehabilitation group | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telerehabilitation group; Assigned to Arm(s): Telerehabilitation group
D: Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: complementary or alternative medicine procedure; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fatigue assessment and management; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: physical therapy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Breast Cancer Survivors: Physical Activity, Inflammation, Fatigue, and Distress
Brief Summary: RATIONALE: Yoga may improve inflammation, fatigue, and depression in female breast cancer survivors.

PURPOSE: This randomized clinical trial is studying how well Hatha yoga works in improving physical activity, inflammation, fatigue, and distress in female breast cancer survivors.


Options:
A: Arm Label: aerobic resistance; Type: EXPERIMENTAL; Interventions: Behavioral: aerobic resistance exercise | Arm Label: home based physical activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: home based health promotion | Intervention Type: BEHAVIORAL; Name: aerobic resistance exercise; Assigned to Arm(s): aerobic resistance | Intervention Type: BEHAVIORAL; Name: home based health promotion; Assigned to Arm(s): home based physical activity
B: Arm Label: Lymphedema Care Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise only; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention | Arm Label: Weight loss only; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Loss Intervention | Arm Label: Exercise and Weight loss combined; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Behavioral: Weight Loss Intervention | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise and Weight loss combined, Exercise only | Intervention Type: BEHAVIORAL; Name: Weight Loss Intervention; Assigned to Arm(s): Exercise and Weight loss combined, Weight loss only
C: Arm Label: Arm I: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Yoga Therapy | Arm Label: Arm II: Wait-List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Yoga Therapy; Assigned to Arm(s): Arm I: Yoga Therapy
D: Arm Label: T+OFS; Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen, Drug: triptorelin | Arm Label: E+OFS; Type: EXPERIMENTAL; Interventions: Drug: exemestane, Drug: triptorelin | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): E+OFS | Intervention Type: DRUG; Name: tamoxifen; Assigned to Arm(s): T+OFS | Intervention Type: DRUG; Name: triptorelin; Assigned to Arm(s): E+OFS, T+OFS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Breast Cancer Survivors: Physical Activity, Inflammation, Fatigue, and Distress
Brief Summary: RATIONALE: Yoga may improve inflammation, fatigue, and depression in female breast cancer survivors.

PURPOSE: This randomized clinical trial is studying how well Hatha yoga works in improving physical activity, inflammation, fatigue, and distress in female breast cancer survivors.


Options:
A: Arm Label: Group I (yoga-based rehabilitation program); Type: EXPERIMENTAL; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Arm Label: Group II (standard care/control); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Intervention Type: PROCEDURE; Name: Quality-of-Life Assessment; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control) | Intervention Type: PROCEDURE; Name: Yoga; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control)
B: Arm Label: Arm I: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Yoga Therapy | Arm Label: Arm II: Wait-List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Yoga Therapy; Assigned to Arm(s): Arm I: Yoga Therapy
C: Arm Label: Yoga Intervention (YOCAS); Type: EXPERIMENTAL; Interventions: Procedure: Yoga Intervention (YOCAS) | Arm Label: Standard Care Control Condition; Type: EXPERIMENTAL; Interventions: Procedure: Standard Care Control Condition | Intervention Type: PROCEDURE; Name: Standard Care Control Condition; Assigned to Arm(s): Standard Care Control Condition | Intervention Type: PROCEDURE; Name: Yoga Intervention (YOCAS); Assigned to Arm(s): Yoga Intervention (YOCAS)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: OTHER; Interventions: Other: Delayed yoga classes | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Delayed yoga classes; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of a Community-based Obesity and Diabetes Prevention Program on Pregnant Outcomes in Pregnant Women
Brief Summary: The general goal of the present study is to assess the impact of a community-based exercise and dietary intervention in pregnant women living in urban areas during and after their pregnancy on the reduction of the risks of both diabetes and obesity in mothers and their offspring.

We hypothesize that a community-based lifestyle intervention program during and after gestation may improve pregnancy outcomes in terms of reducing the risk of developing obesity or type 2 DM in mothers and their children.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise and dietary education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise and dietary education; Assigned to Arm(s): Intervention
B: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Weight Management Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Management | Intervention Type: BEHAVIORAL; Name: Weight Management; Assigned to Arm(s): Weight Management Counseling | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Children of obese women from a RCT; Type: N/A; Interventions: Behavioral: Lifestyle intervention during pregnancy | Arm Label: Children of obese mothers from a RCT, controls; Type: N/A; Interventions: N/A | Arm Label: Children born to normal weight women; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention during pregnancy; Assigned to Arm(s): Children of obese women from a RCT
D: Arm Label: Nutritional counseling + exercise groups; Type: EXPERIMENTAL; Interventions: Behavioral: Nutritional counseling + exercise groups | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nutritional counseling + exercise groups; Assigned to Arm(s): Nutritional counseling + exercise groups

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of a Community-based Obesity and Diabetes Prevention Program on Pregnant Outcomes in Pregnant Women
Brief Summary: The general goal of the present study is to assess the impact of a community-based exercise and dietary intervention in pregnant women living in urban areas during and after their pregnancy on the reduction of the risks of both diabetes and obesity in mothers and their offspring.

We hypothesize that a community-based lifestyle intervention program during and after gestation may improve pregnancy outcomes in terms of reducing the risk of developing obesity or type 2 DM in mothers and their children.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MOMs Healthy Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy MOMs Healthy Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Healthy MOMs Healthy Lifestyle Intervention; Assigned to Arm(s): MOMs Healthy Lifestyle Intervention
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise and dietary education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise and dietary education; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Non-Inferiority Trial of Sulfadoxine-Pyrimethamine Plus Artesunate Compared to Chloroquine for the Treatment of Vivax Malaria in Eastern Afghanistan.
Brief Summary: The purpose of this study was to determine whether the proposed first line treatment for falciparum malaria in this region (sulfadoxine-pyrimethamine + artesunate) would be no worse a treatment for vivax malaria that the standard vivax treatment of chloroquine. In areas where vivax and falciparum malaria co-exist misdiagnosis of vivax malaria as falciparum is not unlikely; it is important to know whether adequate treatment will be received in these cases.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Intervention Type: DRUG; Name: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo; Assigned to Arm(s): 1, 2, 3
B: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate
C: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine + artesunate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): N/A
D: Arm Label: pyronaridine artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): pyronaridine artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): chloroquine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Vascular calcification and endothelial dysfunction (ED) contribute to the development of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Sevelamer, a non-calcium based phosphate binder, has been shown to attenuate cardiovascular calcification in CKD patients while the exact mechanism has not been clarified.

This study was designed to investigate the effect of short-term sevelamer treatment on both serum fetuin-A concentrations and ED seen in CKD patients.


Options:
A: Intervention Type: DRUG; Name: Sevelamer (Renagel), calcium acetate (Phos-ex); Assigned to Arm(s): N/A
B: Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo | Arm Label: KRX-0502 (Ferric Citrate); Type: EXPERIMENTAL; Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo | Intervention Type: DRUG; Name: ferric citrate, ca acetate, sevelamer carbonate, placebo; Assigned to Arm(s): Active Control, KRX-0502 (Ferric Citrate), Placebo
C: Arm Label: Renvela; Type: EXPERIMENTAL; Interventions: Drug: Renvela | Arm Label: Etalpha; Type: EXPERIMENTAL; Interventions: Drug: Etalpha | Intervention Type: DRUG; Name: Renvela; Assigned to Arm(s): Renvela | Intervention Type: DRUG; Name: Etalpha; Assigned to Arm(s): Etalpha
D: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: SBR759A | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Arm Label: arm 4; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Arm Label: arm 5; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): arm 4 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): arm 5

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-blind, Placebo- and Active-control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee.
Brief Summary: The purpose of this study is to evaluate whether tapentadol (CG5503) prolonged-release (PR) tablets at doses of 100-250 mg twice daily provide a better pain relief in patients with moderate to severe chronic pain due to osteoarthritis of the knee than a placebo (a medication without active substance). In addition the tolerability of CG5503 PR will be assessed. One third of the patients will receive CG5503 and one third will receive placebo. For further comparison one third of the patients will receive oxycodone controlled release (CR) at doses of 20-50 mg twice daily which is an active approved pain medication. Please note that tapentadol ER (Extended Release) and tapentadol PR (Prolonged Release) are identical and used interchangeably. This is due to United States of America and European naming conventions.


Options:
A: Arm Label: Matching Placebo (twice daily); Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo (twice daily) | Arm Label: Tapentadol ER (100 to 250 mg twice daily); Type: EXPERIMENTAL; Interventions: Drug: Tapentadol ER (100 to 250 mg twice daily) | Arm Label: Oxycodone CR (20 to 50 mg twice daily); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR (20 to 50 mg twice daily) | Intervention Type: DRUG; Name: Tapentadol ER (100 to 250 mg twice daily); Assigned to Arm(s): Tapentadol ER (100 to 250 mg twice daily) | Intervention Type: DRUG; Name: Matching Placebo (twice daily); Assigned to Arm(s): Matching Placebo (twice daily) | Intervention Type: DRUG; Name: Oxycodone CR (20 to 50 mg twice daily); Assigned to Arm(s): Oxycodone CR (20 to 50 mg twice daily)
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: tapentadol (CG5503) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: oxycodone; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: tapentadol (CG5503); Assigned to Arm(s): 001
C: Arm Label: Tapentadol (CG5503); Type: EXPERIMENTAL; Interventions: Drug: Tapentadol (CG5503) ER | Arm Label: Oxycodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): Oxycodone | Intervention Type: DRUG; Name: Tapentadol (CG5503) ER; Assigned to Arm(s): Tapentadol (CG5503)
D: Arm Label: Tapentadol Prolonged Release; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol Prolonged Release | Intervention Type: DRUG; Name: Tapentadol Prolonged Release; Assigned to Arm(s): Tapentadol Prolonged Release

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Indocin Versus Nifedipine for Preterm Labor Tocolysis - A Randomized Double-Blinded Clinical Trial
Brief Summary: Indomethacin and Nifedipine are commonly used medications for treatment of pre term labor. This study will compare the efficacy and adverse outcomes of oral nifedipine versus oral indomethacin for preterm labor tocolysis in an effort to identify which drug is most effective.

Patients diagnosed with preterm labor who grant consent will be randomized by the pharmacy to receive oral nifedipine or oral indomethacin. Both the patient and primary medical provider will be blinded to the identity of the study drug. An abdominal ultrasound will be performed in the labor and delivery unit prior to the administration of the tocolytic in order to assess fetal position and fluid level, and to document fetal cardiac activity and movement, and will be repeated at 48 hours post-randomization. Following randomization, the patient will be given either 50 mg oral indomethacin with two pills of placebo, or 3 pills each containing 10 mg oral nifedipine for a total of 30 mg. The patients will then receive either 25 mg of oral indomethacin every 6 hours for 48 hours, or 20 mg of oral nifedipine every 6 hours for 48 hours. Tocolysis beyond 48 hours will not be used.


Options:
A: Arm Label: Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin | Arm Label: Nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group one have received Transdermal nitroglycerin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal nitroglycerin | Arm Label: Group two have received nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: nifedipine | Intervention Type: DRUG; Name: Transdermal nitroglycerin; Assigned to Arm(s): Group one have received Transdermal nitroglycerin | Intervention Type: DRUG; Name: nifedipine; Assigned to Arm(s): Group two have received nifedipine
D: Arm Label: Atosiban; Type: EXPERIMENTAL; Interventions: Drug: Atosiban | Arm Label: Nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine

Answer: A